Harnessing the power of HMOs to deliver advanced gut care throughout life

GlyCare® Human Milk Oligosaccharides*

The next generation nutrient supporting gut health for the dietary supplements market.



Consumer demand for gut health is on the rise

Driven by lifestyle disruptions in a fast-paced, ever-changing world, consumers are seeking digestive health solutions more than ever. And most consumers want to support and improve their gut health through diet and supplements. This strong consumer pull creates an opportunity for brands to leverage emerging science to bring new and innovative gut health solutions.



Consumer interest in gut health has increased threefold in the last five years¹



aim to eat foods that encourage a healthy microbiome²



are interested in products that enhance digestion²



said they'd purchase a dietary supplement with HMOs after learning about their health benefits³



Differentiate your next gut health innovation

HMOs are unique, gut-strengthening nutrients found in infant nutrition, scientifically shown to better equip the gut and thus support immune function, digestive health and an active lifestyle.⁴

While the utilization of HMOs in infant formula and food products is a recent innovation, HMOs have been scientifically studied for over 130 years. Thanks to advancements in science, the gut-strengthening benefits of HMOs can now be leveraged throughout life!



dsm-firmenich GlyCare® HMOs do more to build a stronger gut

dsm-firmenich is pioneering the oligosaccharides market with GlyCare® HMOs by delivering innovations for all of life's ages and stages and enabling consumers to do more to stay healthy, active and resilient throughout life

dsm-firmenich GlyCare® HMOs help build a **stronger gut** through **Triple Action**:



Selectively feeds good bacteria so they can flourish



Fosters a thriving community in the gut from the very start



Builds a sturdier house for good bacteria to live

Plus... they support the role of probiotics in the gut by both nourishing and protecting good bacteria.⁴

Uniquely designed to mimic the bioactive components of breastmilk, dsm-firmenich GlyCare® HMOs are the building blocks for optimal digestive health, immunity and active nutrition They also feature key attributes that today's consumers seek:



Clean label



Gluten



Vegetarian



Kosher



Allergen



FODMAP diet friendly

The most comprehensive HMO portfolio worldwide

With the broadest commercial HMO portfolio in the market, GlyCare® HMOs are nature-identical, suitable for a wide variety of applications, and carry a **5-year shelf life.**

The portfolio offers science-backed health benefits across a wide range of products. This is based on scientific exploration around three key areas of human health: gut, brain, and immune health.

GlyCare™ HMO portfolio									
Health benefit	2FL	3FL	2FL/ DF	L LNFP-I	3SL	6SL	LNnT	LNT	
Gut health	•	•	•	•	•	•	•	•	
Immune health	•	•	•	•	•	•	•	•	
Brain health	•	•	•	•	•	•	•	•	

- Clinical data in adults
- No or limited mechanistic data
- Observational and/or wide variety of mechanistic data

Leading the way with regulatory approvals

We are leading the number of global regulatory approvals on HMOs and are continuously expanding our global footprint to make HMOs easily available to our partners. Six single-ingredient or blend HMOs are currently authorized as Novel Foods in the EU and are notified to the U.S. FDA as GRAS, with more to come from our innovation pipeline.

нмо	GRAS Notice	Intended Use	GRAS Uses
2'FL	650	Children [†] Adults	Children's formulas: 2.4 g/L Beverages: Up to 5 g/L Foods: Up to 40 g/kg
LNnT	659	Children [†] Adults	Children's formulas: 0.6 g/L Beverages: Up to 2.5 g/L Foods: Up to 20 g/kg
3′SL	880	Children † Adults	Children's formulas: 0.15–0.20 g/L Beverages: Up to 0.5 g/L Foods: Up to 5 g/kg
6'SL	881	Children † Adults	Children's formulas: 0.3–0.4 g/L Beverages: Up to 1.0 g/L Foods: Up to 10 g/kg
2'FL/DFL	815	Children † Adults	Children's formulas: 1.2–1.6 g/L Beverages: Up to 4 g/L Foods: Up to 40 g/kg
LNT	833	Children [†] Adults	Children's formulas: 0.6 g/L Beverages: Up to 2.0 g/L Foods: Up to 20 g/kg

[†] Ages 3+

Expanding the possibilities around applications

Completed work with 2FL and LNnT includes:

- Fast dissolving tablet^{††}
- Gummies^{††}
- Soft chew^{††}
- Stick pack^{††}
- Chewable tablets††
- Beverages, medical nutrition, and more

†† Patent filed. Country-specific





dsm-firmenich: Your innovative end-to-end partner in HMOs

Widest Portfolio with Legacy of Trust

With the widest portfolio of commercially available HMOs, our extensive history provides assurance of quality as a trusted source for infants, children, and adults

Expert Services to Support your Product Development

We can support your product launch with expertise in innovation and R&D, application development, regulatory and legal advice, scientific support and insights and marketing

Long shelf life and high purity

GlyCare® HMOs feature dry blend powder properties, longest shelflife (5 years), and high purity

Streamline your product development process

The only
manufacturer
of HMOs with
straight, premix
capabilities and
market-ready
solutions under
one roof

Largest market access – world's largest HMO facility

Available for use in more than 165 countries, the largest market access for HMOs worldwide, and in supply with the world's largest HMO facility

Pioneering the future of HMOs

Together with clinical partners, leading universities and external labs, we have supported over 20 studies to advance the understanding of HMOs and how they impact human health

- 1 Google analytics
- 2 Lightspeed/Mintel; KuRunData/Mintel
- 3 Qualtrics Custom HMOs Survey, November 2020. n=417
- 4 (Elison 2016) Elison E, Vigsnaes LK, Rindom Krogsgaard L, et al. Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr. 2016;116(8):1356-1368
- 5 (Illiano 2020). Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. Febs j. 2020;287(5):833–855
- 6 (Iribarren 2020). Iribarren C, Törnblom H, Aziz I, et al. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, doubleblind, placebo-controlled study. Neurogastroenterol Motil. 2020;32(10):e13920
- 7 (Kunz 2012) Kunz C. Historical aspects of human milk oligosaccharides. Adv Nutr. 2012;3(3):430s-439s
- 8 (Bode 2012) Bode L, Jantscher-Krenn E. Structurefunction relationships of human milk oligosaccharides. Adv Nutr. May 1 2012;3(3):383s-91s. doi:10.3945/ an.111.001404
- 9 (Gibson 1994) Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol. Oct 1994;77(4):412–20. doi:10.1111/j.1365–2672.1994.tb03443.x
- 10 (Schwab 2017). Schwab C, Ruscheweyh HJ, Bunesova V, Pham VT, Beerenwinkel N, Lacroix C. Trophic Interactions of Infant Bifidobacteria and Eubacterium hallii during L-Fucose and Fucosyllactose Degradation. Front Microbiol. 2017;8:95
- † As measured by the Bristol Stool Form Scale (BFBS)
- ‡ Based on the IBS Symptom Severity Score (IBS-SSS)

Disclaimer

This document does not constitute a recommendation or guidance for decisions concerning the purchase, use or application of products and does not relieve the user of the product of the obligation to undertake its own suitability, performance or quality testing. It is provided on an "as is" basis. Although the information set forth in this brochure is presented in good faith and believed to be correct, dsm-firmenich Nutritional Products AG and its affiliated companies (hereinafter "dsm-firmenich") makes no representations or warranties, either express or implied, of merchantability, fitness for a particular purpose or of any other nature with respect to information or the products to which information refers. No information set forth in this brochure constitutes a solicitation or offer, or invitation to conclude any legal act of any kind whatsoever. The content of any purchase contract (I.E. Technical data, price and applications of the products of dsm-firmenich) concerning the purchase of dsm-firmenich products is constituted only by the purchase agreement as such and integral parts thereof (specifications in this brochure never form part of a contract). All trademarks, product names, symbols and graphics appearing in this document are the property of dsm-firmenich unless indicated otherwise. All dsm-firmenich trademarks are either registered trademarks or trademarks of dsm-firmenich group of companies in the Netherlands and/or other countries. No license to or right in any such trademarks, trade names, trade secrets, products or other proprietary rights of dsm-firmenich is granted or conferred to any party without a written agreement.



